| 引用本文: | 李伟,陈红斗,陆伟,王梦雷,夏荣,唐毅恒,安洪亮,袁振.2016-2021年国家医保谈判药品可及性研究——基于全国大数据的实证分析[J].中国现代应用药学,2023,40(10):1405-1410. |
| LI Wei,CHEN Hongdou,LU Wei,WANG Menglei,XIA Rong,TANG Yiheng,AN Hongliang,YUAN Zhen.Research on the Accessibility of National Medical Insurance Negotiation Drugs from 2016 to 2021——An Empirical Analysis Based on the National Big Data[J].Chin J Mod Appl Pharm(中国现代应用药学),2023,40(10):1405-1410. |
|
| |
|
|
| 本文已被：浏览 1362次 下载 978次 |
码上扫一扫！ |
|
|
| 2016-2021年国家医保谈判药品可及性研究——基于全国大数据的实证分析 |
|
李伟1, 陈红斗1, 陆伟1, 王梦雷1, 夏荣2, 唐毅恒2, 安洪亮3, 袁振4
|
|
1.徐州医科大学附属宿迁医院药学部, 江苏 宿迁 223800;2.南京鼓楼医院集团仪征医院药剂科, 江苏 仪征 211900;3.南京梅山医院药剂科, 南京 210039;4.宿迁市医疗保障局, 江苏 宿迁 223800
|
|
| 摘要: |
| 目的 调查全国范围内国家医保谈判药品(以下简称"国谈药品")的可及性,为相关部门进一步推动国谈药品的落地提供数据支持。方法 对2016-2021年中国30个省级行政区的1 059家二、三级公立综合医院的国谈药品采购相关数据进行调查分析。结果 2016-2021年国谈药品的可及性整体呈上升趋势;三级公立综合医院国谈药品的可获得率均明显高于二级公立综合医院;2021年国谈药品中西药的平均可获得率明显高于中成药(31.60% vs 17.87%);推行时间较长的国谈药品的可获得率偏高;2021年各省二、三级公立综合医院国谈药品配备率的中位数分别为17.35%和32.93%。结论 国谈药品的可获得率与医疗机构水平、推行落地时间长短、药品适用的疾病谱等因素有关,医疗机构应进一步落实相关政策,保障国谈药品配备。 |
| 关键词: 国家医保谈判药品 可及性 大数据 医疗机构 |
| DOI：10.13748/j.cnki.issn1007-7693.20222377 |
| 分类号:R951 |
| 基金项目:宿迁市科学技术局市级指导性科技计划项目(Z2021114) |
|
| Research on the Accessibility of National Medical Insurance Negotiation Drugs from 2016 to 2021——An Empirical Analysis Based on the National Big Data |
|
LI Wei1, CHEN Hongdou1, LU Wei1, WANG Menglei1, XIA Rong2, TANG Yiheng2, AN Hongliang3, YUAN Zhen4
|
|
1.Department of Pharmacy, the Affiliated Suqian Hospital of Xuzhou Medical University, Suqian 223800, China;2.Department of Pharmacy, Yizheng Hospital of Nanjing Drum Tower Hospital Group, Yizheng 211900, China;3.Department of Pharmacy, Nanjing Meishan Hospital, Nanjing 210039, China;4.Suqian Municipal Medical Insurance Bureau, Suqian 223800, China
|
| Abstract: |
| OBJECTIVE To investigate the availability of national medical insurance negotiation drugs(national negotiated drugs) nationwide, and provide data support for relevant departments to further promote the implementation of national negotiated drugs. METHODS The national negotiated drugs were statistically analyzed 1 059 secondary and tertiary public general hospitals in 30 provincial administrative regions of China during 2016-2021. RESULTS From 2016 to 2021, the general trend of the availability of national negotiated drugs was upward and the availability rate of national negotiated drugs in tertiary general hospitals was significantly higher than that in secondary general hospitals. The average availability rate of Western medicines was significantly higher than Chinese patent medicines(31.60% vs 17.87%). In addition, the availability rate of national negotiated drugs that had been implemented for a long time was comparatively high. In 2021, the medians of the average drug allocation rates of secondary and tertiary public general hospitals in the provinces were 17.35% and 32.93%, respectively. CONCLUSION The availability rate of national negotiated drugs is related to factors such as the level of medical institutions, the length of time for implementation, and the spectrum of diseases to which drugs are adapted. Medical institutions should further implement relevant policies to ensure the availability of negotiation drugs. |
| Key words: national medical insurance negotiation drugs accessibility big data medical institutions |
|
|
|
|
